Every material Form 8-K Kymera Therapeutics, Inc. has filed with the SEC since July 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kymera Therapeutics reported third quarter 2026 results with a net loss of $132.0 million, up from $82.2 million a year earlier, as collaboration revenue fell to zero from $2.8 million. Research and development expenses rose to $128.5 million from $74.1 million, which the company attributed mainly to its STAT6 program. The company also reported Phase 1 healthy volunteer data for its KT-579 degrader and said it had $1.6 billion in cash, with runway into 2029.
Net loss was $132.0 million, or $1.32 per share, versus $82.2 million, or $0.94 per share, in the third quarter of 2025.
Collaboration revenue was zero versus $2.8 million, and the company does not expect additional collaboration revenue in 2026.
Research and development expenses were $128.5 million versus $74.1 million.
Cash, cash equivalents and investments were $1.6 billion as of September 30, 2026; KT-621 BROADEN2 Phase 2b topline data is planned by year-end 2026.
Kymera Therapeutics reported second-quarter 2026 results, with collaboration revenue of $65.0 million, up from $11.5 million a year earlier, mainly from a $45 million Gilead option fee and a $20 million Sanofi milestone. The net loss narrowed to $61.2 million from $76.6 million, though research and development spending rose to $119.5 million from $78.4 million. The company said enrollment in its KT-621 atopic dermatitis Phase 2b trial finished nearly six months early, moving topline data to year-end 2026, and that cash was $1.5 billion as of June 30, 2026.
Collaboration revenue was $65.0 million, versus $11.5 million in Q2 2025, including a $45 million Gilead option fee and a $20 million Sanofi milestone.
Net loss was $61.2 million, or $0.62 per share, versus $76.6 million, or $0.95 per share, a year earlier.
Research and development expenses rose to $119.5 million from $78.4 million.
KT-621 BROADEN2 atopic dermatitis topline data are now expected by year-end 2026, six months earlier than prior guidance of mid-2027.
Kymera Therapeutics said Chief Medical Officer Jared Gollob resigned on July 27, 2026, for personal reasons, and will stay on as an advisor through December 31, 2026. Terence Rooney, M.D., formerly an immunology leader at Johnson & Johnson, became CMO effective the same day. The change is a senior management transition that leads clinical development for the company's oral immunology pipeline.
Jared Gollob resigned as Chief Medical Officer on July 27, 2026, after eight years with the company, citing personal reasons
Terence Rooney, M.D., succeeds Gollob as CMO effective July 27, 2026
Gollob will continue as an advisor until December 31, 2026
Rooney previously served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kymera Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →